Skotak v. Tenneco Resins, Inc.

Court of Appeals for the Fifth Circuit·Decided May 20, 1992·No. 90-1256·Published

Opinion

IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 90-1256

MARY FAYE SKOTAK, GEORGE JERRY SKOTAK, and ERIC NORMAN SKOTAK,

Plaintiffs-Appellants-

Cross-Appellees,

v.

TENNECO RESINS, INC.,

Defendant-Appellee-

Cross-Appellant.

Appeal from the United States District Court for the Northern District of Texas

( March 26, 1992)

ON SUGGESTION FOR REHEARING EN BANC Opinion February 3, 1992, 5 Cir., 1992, 953 F.2d 909

Before WISDOM, KING and BARKSDALE, Circuit Judges. PER CURIAM:

Treating the suggestion for rehearing en banc as a petition for panel rehearing, it is ordered that the petition for panel rehearing is DENIED. No member of the panel nor Judge in regular active service of this Court having requested that the Court be polled on rehearing en banc (Federal Rule of Appellate Procedure and Local Rule 35), the suggestion for Rehearing En Banc is DENIED. The three February 3, 1992, opinions are revised as follows:

BARKSDALE, Circuit Judge:

Paragraph II.B. of my original opinion is withdrawn.

KING, Circuit Judge, concurring in the judgment:

I withdraw my original opinion and concur in the judgment without opinion.

WISDOM, Senior Circuit Judge, dissenting:

I withdraw my original dissenting opinion and substitute the following opinion:* I respectfully dissent.

Judge Barksdale, for the majority of the Court, holds that the plaintiffs failed to show that there was a genuine issue for trial with respect to the adequacy of the manufacturer's warning of the risk of cancer from using Thorotrast.

The plaintiffs introduced in the record copies of two scientific articles and a letter to the Editor of Cancer bearing on the relationship between cancer and Thorotrast.

a. Article 1: Underwood & Hall, Thorotrast Associated Hepatic Angiosarcoma with 36 Years Latency, Cancer 42: 2610-12 (Dec. 1978);

b. Letter to editor, Thorium Dioxide and Liver Cancer, JAMA, Vol. 246, No. 16 (Oct. 16, 1981); and

c. Article 2: Benjamin & Albukerk, Thorotrast-

Induced Angiosarcoma of Liver, N.Y. State J.

Med., pp. 751-53 (Apr. 1982).

*

I have incorporated in this opinion a large part of the opinion Judge King withdrew.

Article 1 referred to an April 1925 study (not introduced in the record) entitled "Some unrecognized dangers in the use and handling of radioactive substances". JAMA 85:1769-1776 (1925). The same article noted that in 1932 the American Medical Association's Council on Pharmacy and Chemistry disapproved of Heyden's introduction of Thorotrast into the United States. Both Articles 1 and 2 referred to a 1947 report in the American Journal of Pathology by McMahon, E., Murphy, A.S., and Bates, M.J., (not introduced in the record) documenting the link between cancer and Thorotrast. The report stated that the use of Thorotrast noticeably declined in the 1950's and continued to decline. The plaintiffs' attorney inartfully attached the articles as exhibits to the Skotaks' opposition to a motion to dismiss for lack of personal jurisdiction, apparently as part of the description of the "background" of their lawsuit. The Skotaks did not suggest the relevancy of the articles before or when TRI moved for summary judgment and did not assert the importance of the articles until they filed their reply brief in this court. It would seem likely that the Skotaks' attorney expected to introduce the articles in the trial on the merits. Nevertheless, they were in the record. We should consider the record as a whole in determining whether there was a dispute over a material fact.

Judge Barksdale would have the Court ignore these articles.

Based on the articles, a reasonable jury could make the following findings:

(1) Thorotrast is a radioactive contrast medium first developed and used in Germany in the 1920's.

(2) The relationship between radioactive chemicals and cancer was documented in a 1925 article by Martland, H.S., Conlan, P., and Knef, J.P. in the Journal of the American Medical Association entitled "Some Unrecognized Dangers in the Use and Handling of Radioactive Substances". JAMA 85:1769-1776 (1925).

(3) In 1932, based primarily on the findings of Martland, H.S., Conlan, P., and Knef, J.P. the American Medical Association's Council on Pharmacy and Chemistry disapproved of the introduction of Thorotrast in the United States.

(4) The relationship between Thorotrast and liver cancer was documented in a 1947 article by McMahon, E., Murphy A.S., and Bates, M.J., "Endothelial Cell Sarcoma of the Liver Following Thorotrast Injections". Am. J.

Pathology, 23:586-611 (1947).

(5) Following the 1947 findings, a large number of reports surfaced linking cancer with previous administration of Thorotrast.

(6) As a result of these reports, the use of Thorotrast as a contrast medium quickly decreased, and by the mid-

1950's Thorotrast was no longer used in the United States as a contrast medium.

This information would permit a jury to find that either of the possible warnings (quoted in Judge Barksdale's opinion) would have been inadequate for failing to mention the evidence linking radioactive chemicals and cancer, and for failing to mention McMahon's finding, of a link between Thorotrast and liver cancer.

Even though the testimony of the actual treating physician is unavailable, the timing of the marked decline in Thorotrast use following the release of information on the cancer risk would permit a reasonable jury to infer: (1) that most physicians were unaware of the cancer risks associated with Thorotrast before the information was released; and (2) once they became aware of the cancer risk, the vast majority of physicians switched to a

substitute contrast medium. In the absence of specific evidence of the treating physician's actual knowledge and likely response, a jury could reasonably infer that Mr. Skotak's treating physician was likely to have the same information available, and would respond in the same manner, as the vast majority of physicians. The articles, therefore, raise a genuine issue of material fact with respect to the adequacy of the warning.

The result reached by Judge Barksdale is contrary to our holdings in Higgenbotham v. Ochsner Foundation Hospital,1 Keiser v. Coliseum Properties, Inc.,2 and Nicholas Acoustics & Specialty Co. v. H & M Constr. Co.3 In those cases we held that, at least where the record is small (as it is in this case), a reviewing court must consider the entire record in determining whether there is a genuine issue of material fact.4 Although, except for Higgenbotham, Fifth Circuit cases touching on this question are not models of clarity, I conclude, unlike Judge Barksdale, that in the

1 607 F.2d 653 (5th Cir. 1979).

2 614 F.2d 406 (5th Cir. 1980).

3 695 F.2d 839 (5th Cir. 1983).

4 See Higgenbotham, 607 F.2d at 656-57; Keiser, 614 F.2d at 410; Nicholas Acoustics, 695 F.2d at 846. Professors Wright, Miller, and Kane agree: "The parties need not formally offer their outside matter as evidence or have it marked as an exhibit at the hearing on the motion. Given this process, the court is obliged to take account of the entire setting of the case on a Rule 56 motion. In addition to the pleadings, it will consider all papers of record, as well as any material prepared for the motion that meets the standard prescribed in Rule 56(e)." 10A Wright, Miller & Kane, Federal Practice and Procedure § 2721, at 44 (2d ed. 1983).

circumstances of this case precedent in the Fifth Circuit compels consideration of the evidence the Skotaks failed to point out.

Free access — add to your briefcase to read the full text and ask questions with AI

Skotak v. Tenneco Resins, Inc., (5th Cir. 1992).

Skotak v. Tenneco Resins, Inc. (Skotak v. Tenneco Resins, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related